CVSD Stock Overview
CVS Health Corporation provides health solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
CVS Health Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.48 |
| 52 Week High | US$68.12 |
| 52 Week Low | US$61.24 |
| Beta | 0.51 |
| 1 Month Change | -3.88% |
| 3 Month Change | -3.88% |
| 1 Year Change | -1.40% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVSD | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 1.7% |
| 1Y | -1.4% | -29.7% | 1.4% |
Return vs Industry: CVSD exceeded the UK Healthcare industry which returned -29.7% over the past year.
Return vs Market: CVSD underperformed the UK Market which returned 1.1% over the past year.
Price Volatility
| CVSD volatility | |
|---|---|
| CVSD Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CVSD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CVSD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 259,500 | Karen Lynch | www.cvshealth.com |
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
CVS Health Corporation Fundamentals Summary
| CVSD fundamental statistics | |
|---|---|
| Market cap | €79.01b |
| Earnings (TTM) | €7.79b |
| Revenue (TTM) | €332.76b |
10.1x
P/E Ratio0.2x
P/S RatioIs CVSD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVSD income statement (TTM) | |
|---|---|
| Revenue | US$356.62b |
| Cost of Revenue | US$303.35b |
| Gross Profit | US$53.28b |
| Other Expenses | US$44.93b |
| Earnings | US$8.34b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 6.62 |
| Gross Margin | 14.94% |
| Net Profit Margin | 2.34% |
| Debt/Equity Ratio | 78.6% |
How did CVSD perform over the long term?
See historical performance and comparison